Targeted Ketamine Delivery

Description:

We are scheduled to embark on a unique first-in-human interdisciplinary study, to use targeted delivery of psychoactive compounds to specific brain regions, guided by personalized neuroimaging and utilizing noninvasive brain stimulation.

The Challenge:

Several psychedelic and non-psychedelic compounds are being studied and/or used for clinical purposes. However, such substances operate systemically and have nonspecific effects. Put differently, even though they are used for a specific target, they impact other brain and body processes and come with a substantial list of side effects.

Our Study:

To solve this problem, we joined forces with the laboratory of Dr. Raag Airan at Stanford Medicine’s Department of Radiology, to develop and test a way to deliver these compounds specifically to the target, thereby avoiding systemic effects.

In late 2024, we plan to start the first-ever trial in humans, to deliver ketamine to a region in the brain that participates in pain experiences. To achieve this goal, we will use an interdisciplinary approach combining neurochemistry, neurobiology, neuroimaging, and noninvasive brain stimulation.

Join Us on this Journey:

We invite you to stay connected with us as we delve into this exciting frontier of psychiatric treatment. Follow our progress, access research findings, and be part of the dialogue that could lead to a brighter future for individuals battling psychiatric and neurological conditions.

Together, we aim to unlock the potential of targeted drug delivery, to allow us precision psychedelic medicine, with maximal safety and minimal side effects.